USFDA issues CRL for proposed biosimilar Pegfilgrastim: Biocon

The company said it does not expect the CRL to impact the timing of the launch of biosimilar Pegfilgrastim in the US market.

Source: The Economic Times Healthcare and Biotech News - October 10, 2017 Category: Pharmaceuticals Source Type: news